Angiochem's ANG1005 Shows Clinical Benefit and Prolonged Survival in Phase II Trial
06 juin 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - June 06, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, presented data during a...
Angiochem to Present at ASCO 2016
18 mai 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - May 18, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an...
Angiochem Announces End-of-Phase 2 Meeting With FDA
04 mai 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - May 04, 2016) - Angiochem, a biotechnology company developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain...
Angiochem Appoints Executive Chairman and Elects New Board of Directors
28 avr. 2016 07h00 HE
|
Angiochem
MONTREAL, QC--(Marketwired - April 28, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, has appointed Mr. John...
La société américaine National Brain Tumor Society remet à Angiochem le prix de l'innovation pour souligner le développement de nouveaux traitements contre le cancer de cerveau
15 févr. 2011 07h00 HE
|
Angiochem Inc.
MONTRÉAL, CANADA et WATERTOWN, MASSACHUSETTS--(Marketwire - 15 fév. 2011) - Angiochem, inc., une entreprise de biotechnologie au stade clinique, et la National Brain Tumor...
Angiochem Receives Innovation Award From the National Brain Tumor Society for Advancing the Development of Novel Brain Cancer Treatments
15 févr. 2011 07h00 HE
|
Angiochem Inc.
MONTREAL, CANADA, and WATERTOWN, MASSACHUSETTS--(Marketwire - Feb. 15, 2011) - Angiochem, Inc., a clinical stage biotechnology company, and the National Brain Tumor Society (NBTS), a...